Vaxcyte, Inc. PCVX
We take great care to ensure that the data presented and summarized in this overview for Vaxcyte, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PCVX
View all-
Ra Capital Management, L.P. Boston, MA12.2MShares$402 Million9.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$397 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X011.8MShares$388 Million0.25% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$327 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA6.42MShares$211 Million0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.11MShares$201 Million0.05% of portfolio
-
State Street Corp Boston, MA4.41MShares$145 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.54MShares$117 Million0.02% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.2MShares$105 Million10.18% of portfolio
-
Franklin Resources Inc San Mateo, CA3.09MShares$102 Million0.04% of portfolio
Latest Institutional Activity in PCVX
Top Purchases
Top Sells
About PCVX
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Insider Transactions at PCVX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 12
2025
|
Olivier Brandicourt Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,148
+50.0%
|
-
|
|
Jun 12
2025
|
Teri Loxam Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,041
+22.94%
|
-
|
|
Jun 12
2025
|
Halley E Gilbert Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,041
+22.94%
|
-
|
|
Jun 12
2025
|
Carlos V Paya Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,041
+39.85%
|
-
|
|
Jun 12
2025
|
Anne S Drapeau Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,041
+22.94%
|
-
|
|
Jun 12
2025
|
Jacks Lee Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,041
+39.85%
|
-
|
|
Jun 12
2025
|
John Furey Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,041
+50.0%
|
-
|
|
Jun 12
2025
|
Heath Lukatch Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,041
+15.01%
|
-
|
|
Apr 08
2025
|
Heath Lukatch Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+18.94%
|
$126,000
$18.75 P/Share
|
|
Apr 07
2025
|
Andrew Guggenhime PRESIDENT AND CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,777
+3.49%
|
$95,540
$20.93 P/Share
|
|
Apr 04
2025
|
Grant Pickering CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
20,533
+1.94%
|
$266,929
$13.14 P/Share
|
|
Mar 27
2025
|
Grant Pickering CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
57,938
+10.23%
|
-
|
|
Mar 05
2025
|
Mikhail Eydelman SVP, GEN COUNSEL & CORP SEC |
SELL
Open market or private sale
|
Direct |
5,000
-3.68%
|
$355,000
$71.28 P/Share
|
|
Mar 05
2025
|
Mikhail Eydelman SVP, GEN COUNSEL & CORP SEC |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+9.69%
|
$105,000
$21.41 P/Share
|
|
Mar 03
2025
|
Andrew Guggenhime PRESIDENT AND CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,809
-2.91%
|
$274,248
$72.1 P/Share
|
|
Mar 03
2025
|
Mikhail Eydelman SVP, GEN COUNSEL & CORP SEC |
SELL
Payment of exercise price or tax liability
|
Direct |
616
-1.46%
|
$44,352
$72.1 P/Share
|
|
Mar 03
2025
|
Elvia Cowan SVP, FINANCE |
SELL
Payment of exercise price or tax liability
|
Direct |
325
-1.33%
|
$23,400
$72.1 P/Share
|
|
Mar 03
2025
|
Grant Pickering CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
7,984
-1.58%
|
$574,848
$72.1 P/Share
|
|
Mar 03
2025
|
Jim Wassil CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,015
-1.95%
|
$217,080
$72.1 P/Share
|
|
Mar 03
2025
|
Jim Wassil CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
8,000
-2.48%
|
$584,000
$73.45 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 153K shares |
|---|---|
| Exercise of conversion of derivative security | 397K shares |
| Payment of exercise price or tax liability | 53.3K shares |
|---|---|
| Bona fide gift | 77.3K shares |
| Open market or private sale | 365K shares |